The regulator requires Lilly to evaluate the “unexpected serious” risks associated with Foundayo.
Cochrane’s research looked at 17 clinical trials of anti-amyloid drugs in Alzheimer’s disease.
Interna’s MNM molecules will be integrated with targeting approaches for enhancing functional activity.
Aligos remains eligible for up to $420m in milestones and tiered, high single-digit royalties on Amoytop’s net sales.
Amazon has already collaborated with Memorial Sloan Kettering Cancer Center with its AI software.
This guidance emphasises the potential of NGS methods in mitigating safety risks associated with therapies incorporating genome editing.
